Phaseline

Companies › Cibus Therapeutics

Cibus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Gastroenterology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CBT-248–Phase 1Chronic PancreatitisMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07905053CBT-248Phase 1Chronic PancreatitisGastroenterologyMay 2027

From the company's SEC filings

Cash of $20m on 2026-06-30; operating cash outflow about $42m a year; runway about 6 months at that burn, to Dec 2026

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.